Tumor infiltrating lymphocytes (TILs) improve prognosis in patients with triple negative breast cancer (TNBC)

Sylvia Adams, Lori J. Goldstein, Joseph A. Sparano, Sandra Demaria, Sunil Badve

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

pon analysis of archived primary tumors of 482 patients with triple negative breast cancer (TNBC) enrolled in two randomized Phase III adjuvant chemotherapy trials, we have found that tumor infiltrating lymphocytes (TILs), as assessed and quantified by hematoxylin and eosin (H&E) staining are a robust and independent predictor of disease-free survival (DFS), distant recurrence-free interval (DRFI) and overall survival (OS).1 Our findings provide confirmation of results observed in TNBC in a European adjuvant chemotherapy dataset and therefore elevate TILs as prognostic biomarker for operable TNBC to level I evidence.

Original languageEnglish (US)
Pages (from-to)1-3
Number of pages3
JournalOncoImmunology
Volume4
Issue number9
DOIs
StatePublished - Jan 1 2015

Fingerprint

Triple Negative Breast Neoplasms
Tumor-Infiltrating Lymphocytes
Adjuvant Chemotherapy
Hematoxylin
Eosine Yellowish-(YS)
Disease-Free Survival
Biomarkers
Staining and Labeling
Recurrence
Survival
Neoplasms

Keywords

  • Biomarker
  • Breast cancer
  • TNBC
  • Tumor infiltrating lymphocytes

ASJC Scopus subject areas

  • Immunology and Allergy
  • Oncology
  • Immunology

Cite this

Tumor infiltrating lymphocytes (TILs) improve prognosis in patients with triple negative breast cancer (TNBC). / Adams, Sylvia; Goldstein, Lori J.; Sparano, Joseph A.; Demaria, Sandra; Badve, Sunil.

In: OncoImmunology, Vol. 4, No. 9, 01.01.2015, p. 1-3.

Research output: Contribution to journalArticle

Adams, Sylvia ; Goldstein, Lori J. ; Sparano, Joseph A. ; Demaria, Sandra ; Badve, Sunil. / Tumor infiltrating lymphocytes (TILs) improve prognosis in patients with triple negative breast cancer (TNBC). In: OncoImmunology. 2015 ; Vol. 4, No. 9. pp. 1-3.
@article{4eed75e3167c484face6299584b54d87,
title = "Tumor infiltrating lymphocytes (TILs) improve prognosis in patients with triple negative breast cancer (TNBC)",
abstract = "pon analysis of archived primary tumors of 482 patients with triple negative breast cancer (TNBC) enrolled in two randomized Phase III adjuvant chemotherapy trials, we have found that tumor infiltrating lymphocytes (TILs), as assessed and quantified by hematoxylin and eosin (H&E) staining are a robust and independent predictor of disease-free survival (DFS), distant recurrence-free interval (DRFI) and overall survival (OS).1 Our findings provide confirmation of results observed in TNBC in a European adjuvant chemotherapy dataset and therefore elevate TILs as prognostic biomarker for operable TNBC to level I evidence.",
keywords = "Biomarker, Breast cancer, TNBC, Tumor infiltrating lymphocytes",
author = "Sylvia Adams and Goldstein, {Lori J.} and Sparano, {Joseph A.} and Sandra Demaria and Sunil Badve",
year = "2015",
month = "1",
day = "1",
doi = "10.4161/2162402X.2014.985930",
language = "English (US)",
volume = "4",
pages = "1--3",
journal = "OncoImmunology",
issn = "2162-4011",
publisher = "Landes Bioscience",
number = "9",

}

TY - JOUR

T1 - Tumor infiltrating lymphocytes (TILs) improve prognosis in patients with triple negative breast cancer (TNBC)

AU - Adams, Sylvia

AU - Goldstein, Lori J.

AU - Sparano, Joseph A.

AU - Demaria, Sandra

AU - Badve, Sunil

PY - 2015/1/1

Y1 - 2015/1/1

N2 - pon analysis of archived primary tumors of 482 patients with triple negative breast cancer (TNBC) enrolled in two randomized Phase III adjuvant chemotherapy trials, we have found that tumor infiltrating lymphocytes (TILs), as assessed and quantified by hematoxylin and eosin (H&E) staining are a robust and independent predictor of disease-free survival (DFS), distant recurrence-free interval (DRFI) and overall survival (OS).1 Our findings provide confirmation of results observed in TNBC in a European adjuvant chemotherapy dataset and therefore elevate TILs as prognostic biomarker for operable TNBC to level I evidence.

AB - pon analysis of archived primary tumors of 482 patients with triple negative breast cancer (TNBC) enrolled in two randomized Phase III adjuvant chemotherapy trials, we have found that tumor infiltrating lymphocytes (TILs), as assessed and quantified by hematoxylin and eosin (H&E) staining are a robust and independent predictor of disease-free survival (DFS), distant recurrence-free interval (DRFI) and overall survival (OS).1 Our findings provide confirmation of results observed in TNBC in a European adjuvant chemotherapy dataset and therefore elevate TILs as prognostic biomarker for operable TNBC to level I evidence.

KW - Biomarker

KW - Breast cancer

KW - TNBC

KW - Tumor infiltrating lymphocytes

UR - http://www.scopus.com/inward/record.url?scp=84944452392&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944452392&partnerID=8YFLogxK

U2 - 10.4161/2162402X.2014.985930

DO - 10.4161/2162402X.2014.985930

M3 - Article

VL - 4

SP - 1

EP - 3

JO - OncoImmunology

JF - OncoImmunology

SN - 2162-4011

IS - 9

ER -